TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity / Shallis, R.M., Daver, N.G., Altman, J.K., Hasserjian, R.P., Kantarjian, H.M., Platzbecker, U., Santini, V., Wei, A.H., Sallman, D.A., Zeidan, A.M.. - In: CANCER. - ISSN 0008-543X. - ELETTRONICO. - 129:(2023), pp. 175-180. [10.1002/cncr.34535]
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
Santini, Valeria;
2023
Abstract
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cancer - 2022 - Shallis - TP53%E2%80%90altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
208.17 kB
Formato
Adobe PDF
|
208.17 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
